Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of Other Oncogene Mutations for Anti-EGFR Monoclonal Antibodies Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer: Multicenter Randomized Phase III Trial

NCT06226857 is registered in ClinicalTrials.gov with City Clinical Oncology Hospital No 1 as lead sponsor.

NCT NCT06226857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06226857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of Other Oncogene Mutations for Anti-EGFR Monoclonal Antibodies Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer: Multicenter Randomized Phase III Trial
Lead sponsor
City Clinical Oncology Hospital No 1
Phase
Phase 3
Overall status
Recruiting
Start date
January 17, 2024
Completion date
December 31, 2027
Enrollment
355 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, colorectal neoplasms, molecular sequence variation